Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Swearingen

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Arthritis Care & Research|March 2, 2010
RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety secondsTheodore Pincus, Christopher J Swearingen, Martin J Bergman, et al.
Journal of Burn Care & Research : Official Publication of the American Burn Association|May 15, 2014
Effect of virtual reality on adolescent pain during burn wound careDebra Jeffs, Dona Dorman, Susan Brown, et al.
Pharmacotherapy|November 18, 2000
Oxandrolone in trauma patientsJ M Gervasio, R N Dickerson, J Swearingen, et al.
Clinical Neuropharmacology|August 2, 2008
Caffeine and progression of Parkinson diseaseDavid K Simon, Christopher J Swearingen, Robert A Hauser, et al.
Clinical and Experimental Rheumatology|January 14, 2025
A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritisYusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, et al.
Archives of Neurology|July 15, 2009
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) ExperienceSotirios A Parashos, Christopher J Swearingen, Kevin M Biglan, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1Michael J Moser, Meta Ruckstuhl, Christine A Larsen, et al.
Pediatric Cardiology|November 3, 2016
Improved Survival While Waiting and Risk Factors for Death in Pediatric Patients Listed for Cardiac TransplantationDala Zakaria, Elizabeth Frazier, Michiaki Imamura, et al.
Rheumatology and Therapy|October 30, 2023
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm StudyMark S Fineman, Timothy E McAlindon, Christian Lattermann, et al.
Clinical and Experimental Rheumatology|January 14, 2025
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patientsYusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Arthritis Care & Research|March 2, 2010
RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety secondsTheodore Pincus, Christopher J Swearingen, Martin J Bergman, et al.
Journal of Burn Care & Research : Official Publication of the American Burn Association|May 15, 2014
Effect of virtual reality on adolescent pain during burn wound careDebra Jeffs, Dona Dorman, Susan Brown, et al.
Pharmacotherapy|November 18, 2000
Oxandrolone in trauma patientsJ M Gervasio, R N Dickerson, J Swearingen, et al.
Clinical Neuropharmacology|August 2, 2008
Caffeine and progression of Parkinson diseaseDavid K Simon, Christopher J Swearingen, Robert A Hauser, et al.
Clinical and Experimental Rheumatology|January 14, 2025
A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritisYusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, et al.
Archives of Neurology|July 15, 2009
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) ExperienceSotirios A Parashos, Christopher J Swearingen, Kevin M Biglan, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1Michael J Moser, Meta Ruckstuhl, Christine A Larsen, et al.
Pediatric Cardiology|November 3, 2016
Improved Survival While Waiting and Risk Factors for Death in Pediatric Patients Listed for Cardiac TransplantationDala Zakaria, Elizabeth Frazier, Michiaki Imamura, et al.
Rheumatology and Therapy|October 30, 2023
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm StudyMark S Fineman, Timothy E McAlindon, Christian Lattermann, et al.
Clinical and Experimental Rheumatology|January 14, 2025
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patientsYusuf Yazici, Jeyanesh R S Tambiah, Christopher J Swearingen, et al.
Pageof 8